MS and Demyelinating Disorders

The next important area of therapeutic development in MS appears to be in disease damage repair.

The monoclonal antibody has shown continued success up to 8 years in clinical trials.

One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.

The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.

Neurology News Network for the week of Oct. 12, 2018.

This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.

The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.

The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.

The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.

An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.

If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.

With a phase I trial of the therapy underway, EHP-101 is one step closer to potentially showing an effect on the pathology of multiple sclerosis.

The majority of relapses were treated in an outpatient setting, and that the rate of outpatient relapses very sharply declined during pregnancy.

Based on the findings in this early phase, Emerald Health expects to start phase II trials in both MS and scleroderma.

A new analysis of more than a dozen clinical trials has shown no increase in stroke risk for patients with MS, who have shown a higher risk than the general population.

Neurology News Network for the week of September 22, 2018.

Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.

Neurology News Network for the week of September 15, 2018.

After its approval in May for pediatric MS, the data displayed its efficacy in comparison to standard therapy.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.